32
Participants
Start Date
December 31, 2014
Primary Completion Date
November 30, 2016
Study Completion Date
November 30, 2016
Ovasave
During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
Placebo
During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
Medical University Innsbruck, Innsbruck
Medical University of Vienna, Vienna
Cliniques Universitaires Saint-Luc, Brussels
UZ Gent, Ghent
UZ Gasthuisberg, Leuven
CHU Liege, Liège
CHU d'Amiens Sud, Amiens
CHU de Besançon, Hôpital Jean Minjoz, Besançon
Hôpital Beaujon, Clichy
Hôpital Henri Mondor, Créteil
CHRU de Lille, Hôpital Claude Huriez, Lille
CHU de Nancy, Hôpital de Brabois Adulte, Nancy
CHU de Nice, Hôpital de l'Archet 2, Nice
Hôpital Saint-Louis, Paris
Hôpital St-Antoine, Paris
CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac
CHU de Toulouse, Hôpital Rangueil, Toulouse
Krankenhaus Waldfriede e.V., Berlin
Markus Hospital, Frankfurt am Main
Hannover Medical School, Hanover
University Hospital Schleswig-Holstein, Kiel
Gastroenterologische Gemeinschaftpraxis, Minden
Universitätsklinik Ulm, Ulm
Azienda Ospedaliero-Universitaria Careggi, Florence
Istituto Clinico Humanitas, Milan
Complesso Integrato Columbus, Roma
Ospedale San Camillo-Forlanini, Roma
Guy's and St Thomas' NHS Foundation Trust, London
Southampton General Hospital, Southampton
Lead Sponsor
TxCell
INDUSTRY